A U.S. attempt to annex Greenland would violate core principles of international law, including the prohibition on territorial acquisition by force under the UN Charter. To impose meaningful, non-violent costs and potentially deter or reverse such aggression, focused boycotts in the medical and pharmaceutical sectors offer substantial leverage. The U.S. dominates global pharmaceutical innovation, exports, and high-value drug markets, while relying heavily on international collaborations for research and supply chains. Coordinated actions by the EU, BRICS nations, and others could exploit these vulnerabilities. Below is a detailed, fact-based exploration of viable boycott measures centered on medicine, drawing from precedents like sanctions on Russia (post-2022) and Iran (post-2012), where restrictions led to drug shortages, industry pivots, and economic strain despite humanitarian exemptions. 1. Coordinated Import Bans or High Tariffs on U.S. Pharmaceutical Exports The U.S. exported pharmaceuticals worth approximately $94-130 billion…